What COMP360 Durability Data Can Tell Us

The question after response

In psychedelic medicine, early improvement gets a lot of attention.

That makes sense. Rapid symptom reduction is clinically meaningful, especially in treatment-resistant depression, where many patients have already tried multiple treatments without enough relief. When someone has lived with depression for years, any signal of meaningful improvement matters.

But in depression care, the first question is rarely the only question.

The next question is often harder.

How long does the improvement last?

That is why durability data matters.

COMPASS Pathways recently reported six-month data from its second Phase 3 trial of COMP360 psilocybin in treatment-resistant depression. The topline message was that benefit appeared durable for a meaningful subset of participants through 26 weeks, with no new safety findings reported. For a field that often focuses on the acute psychedelic session, that is an important development.

I’ve had the opportunity to work extensively with COMP360, and I can attest to the fact that, under proper conditions, with psychological support, it has the potential to be life changing and life saving when other medications have failed. And this impact appears to be relatively long lasting.

But durability needs careful interpretation.

A sustained response is not the same as a cure. A durable signal in a trial is not the same as guaranteed long-term benefit in real-world practice. And a promising Phase 3 program does not answer every clinical question that psychiatrists, therapists, patients, families, payers, and regulators will need to ask.

The more useful conversation is not simply, “Does it work?”

The better question is: what does this durability data actually tell us about caring for complex patients over time?

Why durability matters in treatment-resistant depression

Treatment-resistant depression is not a simple condition.

It usually means that a person has not responded adequately to at least two appropriate treatment trials. But that definition does not capture the full clinical reality. Many patients with treatment-resistant depression have long illness duration, recurrent episodes, comorbid anxiety, trauma histories, substance use concerns, medical illness, sleep disturbance, chronic pain, suicidality, medication side effects, and years of disappointment with prior treatments.

In that context, a rapid antidepressant effect is meaningful.

But durability may matter even more.

A brief improvement can still be valuable. Sometimes a few days or weeks of relief can help someone reconnect with hope, re-engage in therapy, make decisions, repair relationships, or step out of an acute crisis. But for a treatment to become part of routine psychiatric care, clinicians also need to understand what happens after the initial improvement.

Does the person stay well?

Do symptoms gradually return?

Are there identifiable predictors of relapse?

What kind of follow-up helps maintain gains?

Does the benefit depend on additional dosing?

How does this compare with other treatment options?

Those are not skeptical questions in the dismissive sense. They are clinical questions. They are the questions that make a treatment usable.

What the COMP360 data appear to show

The newly reported COMP006 data suggest that some participants treated with COMP360 maintained clinically meaningful benefits through six months. In the 25 mg arm, COMPASS reported that 39% of participants achieved at least a 25% reduction in MADRS score by Week 6 and maintained benefit on average through Week 26. The company also reported that retreatment during Part B further enhanced benefit for some participants, with nearly 30% of Week 6 responders later entering remission after retreatment.

They suggest that benefit may not be limited to the immediate aftermath of the dosing session. They also suggest that retreatment may matter for some patients, which raises a clinically important question: if psilocybin treatment is approved in the future, will the model of care involve a single treatment, two planned treatments, intermittent retreatment, or something more individualized?

The answer matters for implementation.

A treatment model involving one supervised dosing session has one kind of infrastructure challenge. A model involving repeated or flexible retreatment has another. Clinics would need to think about scheduling, staffing, room availability, monitoring, medication management, psychological support, adverse event tracking, and the practical realities of caring for people whose symptoms may improve, partially improve, relapse, or fluctuate.

Durability is not just an efficacy question.

It is an implementation question.

Safety over time

The six-month data also raise the issue of safety follow-up.

In the recent COMPASS report, COMP360 was described as generally well tolerated, with no new safety findings. The company reported that most treatment-emergent adverse events were transient and occurred predominantly on the day of dosing. The most common adverse events included nausea, headache, anxiety, and visual hallucination.

That safety profile is encouraging.

But safety in psychedelic medicine is broader than the dosing day.

When clinicians think about real-world care, safety includes screening before treatment, monitoring during the acute experience, follow-up afterward, and attention to what happens weeks or months later. It includes suicidality, mood destabilization, sleep changes, substance use patterns, medication changes, psychosis risk, bipolar spectrum risk, trauma activation, dissociation, and the possibility that someone may interpret an experience in a way that changes behavior.

This does not mean psychedelic medicine should be feared.

It means it should be treated as serious clinical care.

Psychedelics are often safer than the public assumes. The greater challenge is that many patients seeking them are medically and psychiatrically complex. That is especially true in treatment-resistant depression, where the patient population may include long illness duration, multiple medication trials, polypharmacy, comorbid diagnoses, and significant functional impairment.

A safety signal in a trial is important.

But implementation requires a safety system.

The difference between trial patients and real-world patients

Clinical trials are necessary. They help establish whether a treatment has evidence of efficacy and safety under controlled conditions. They use defined inclusion and exclusion criteria, structured assessments, trained teams, monitoring protocols, and careful follow-up. That is exactly what responsible drug development requires.

But real-world psychiatry is messier.

Patients often arrive with diagnostic uncertainty. Depression may overlap with bipolar spectrum illness, trauma-related symptoms, ADHD, substance use, personality structure, grief, medical illness, chronic pain, or neurodevelopmental factors. Medication regimens may be complicated. Some patients are stable enough to participate in an intensive treatment model. Others may not be.

This is where psychedelic medicine needs humility.

If COMP360 eventually becomes available, clinicians will not only ask whether the treatment can reduce depression scores in a trial. They will need to ask who is actually appropriate for treatment in practice.

Who should be screened out?

Who needs more stabilization first?

How should clinicians manage antidepressants, mood stabilizers, antipsychotics, benzodiazepines, stimulants, or medications for medical illness?

How should clinics evaluate bipolar risk?

What follow-up is enough?

What happens if a person improves dramatically and then relapses?

What happens if a person has a meaningful subjective experience but little symptom change?

What happens if a person feels destabilized after the session?

These are not reasons to avoid psychedelic medicine.

They are reasons to build it carefully.

Durability is not the same as cure

One of the most important communication points is that durability should not be confused with cure.

Six months of maintained benefit is meaningful. It may be especially meaningful in a population with chronic, treatment-resistant depression. But depression is often recurrent. Some patients may have sustained remission. Others may have partial response. Others may relapse. Some may not respond at all.

This is true across psychiatry.

We do not usually expect a single intervention to permanently resolve every dimension of a recurrent mood disorder. Even when treatments are highly effective, clinicians still think about relapse prevention, maintenance care, comorbidity, psychosocial stress, sleep, substance use, therapy, family context, medical illness, and ongoing monitoring.

Psychedelic medicine should not be exempt from that same realism.

If anything, it needs more of it.

The public conversation can easily drift toward the idea that a powerful acute experience should create permanent transformation. Sometimes people do describe enduring change after psychedelic experiences. Those reports should not be dismissed. But they also should not be universalized.

Durability data help bring the conversation back to evidence.

How many people maintain benefit?

For how long?

Under what conditions?

With how much support?

After how many treatments?

With what risk?

Those are the questions that matter.

The implementation question

I keep returning to implementation because it may become one of the most important questions in psychedelic psychiatry.

For COMP360, that question includes the medication itself, but also the treatment model around it. Psilocybin treatment requires preparation, a supervised dosing session, monitoring, psychological support, and follow-up. Depending on the protocol, sessions may be long. Facilities may need appropriate space. Staff need training. Emergency procedures need to be clear. Boundaries need to be strong. Documentation needs to be careful. Medication interactions need to be evaluated. Adverse events need to be tracked.

Then there is access.

Who will be able to receive treatment if it is approved?

Will insurance cover it?

Will clinics have the space and staffing to deliver it?

Will rural patients have access?

Will people with complex psychiatric histories be excluded?

Will communities that helped preserve psychedelic knowledge be respected, included, or pushed aside as the field becomes more medicalized and commercialized?

These questions are not separate from the science.

They determine whether a promising treatment becomes meaningful care.

Indigenous foundations and modern durability data

COMP360 is a synthetic psilocybin formulation studied within a modern pharmaceutical and regulatory framework. That framework can generate valuable evidence. It can help clarify dosing, safety, efficacy, durability, and implementation. It may also help expand access if a treatment is eventually approved.

But modern research does not replace the Indigenous and ancestral foundations of psychedelic practice.

Long before contemporary trials, many cultures developed sophisticated relationships with psychoactive plants and fungi, often emphasizing preparation, context, community, ceremony, meaning, and responsibility. Western clinical research uses different language, but it is still wrestling with related questions: who is ready, what container is needed, what happens afterward, and how should powerful experiences be integrated into life?

That does not mean clinical trials should imitate ceremony. Careless imitation can become extractive. But it does mean modern medicine should remain humble.

Durability is not only a rating scale question. It is also a question of what supports change over time.

Modern science can measure symptoms across weeks and months. It can help identify patterns of response and relapse. It can establish regulatory evidence. But it cannot fully capture the relational, cultural, spiritual, and contextual dimensions that have always been part of psychedelic practice.

A mature field should be able to honor both.

What clinicians should take from this

The COMP360 durability data are encouraging.

They suggest that, for some people with treatment-resistant depression, benefit may persist well beyond the acute dosing period. They also raise important questions about retreatment, relapse, remission, safety follow-up, and clinical delivery.

That is where the real conversation begins.

Not with the headline.

Not with hype.

Not with fear.

With careful interpretation.

Does it work? The data suggest a clinically meaningful signal for some patients.

Is it reasonably safe? The reported safety profile is encouraging, but real-world safety will depend on screening, monitoring, and follow-up.

Can real clinicians realistically deliver it to real patients? That remains one of the central implementation questions.

Psychedelic medicine will not mature simply because trials are positive. It will mature if the field can translate evidence into careful care.

Durability data help us ask better questions.

What lasts?

For whom?

At what cost?

With what support?

And what kind of clinical system is needed to make benefit more likely and harm less likely?

That is the conversation worth having.